Brief: Herantis Pharma Says Phase 1B Trial For Parkinson’s Treatment Meets Main, Secondary Goals
07/10/2025 18:27
Oct 7 (Reuters) - Herantis Pharma Oyj HRTIS.HE: HERANTIS PHARMA PRESENTS POSITIVE TOPLINE DATA FOR HER-096 IN PHASE 1B TRIAL FOR PEOPLE LIVING WITH PARKINSON’S DISEASE HERANTIS PHARMA OYJ - TRIAL MEETS ALL PRIMARY AND SECONDARY ENDPOINTS HERANTIS PHARMA OYJ - HER-096 DOSES SAFE AND WELL TOLERATED IN TRIAL HERANTIS PHARMA OYJ - FULL DATASET EXPECTED BEFORE END OF 2025 HERANTIS PHARMA OYJ - DATA INDICATE THAT TWICE-WEEKLY DOSING REGIMEN WITH 300 MG DOSE SUITABLE FOR PHASE 2 TRIAL Source text: ID:nGNX7SK3Zc Further company coverage: HRTIS.HE ((Reuters.Briefs@thomsonreuters.com;))